; (2) minority health organizations; (3) health care researchers and providers, including those with expertise in minority health; (4) Federal health agencies, including the Office of Minority Health, the National Institute on Minority Health and Health Disparities, and the National Institutes of Health; and (5) other experts as the Secretary determines appropriate. (c) Diseases Screening guidelines for minority populations shall be developed as appropriate under subsection (a) for— (1) hypertension; (2) hypercholesterolemia; (3) diabetes; (4) cardiovascular disease; (5) cancers, including breast, prostate, colon, cervical, and lung cancer; (6) other pulmonary problems including sleep apnea; (7) asthma; (8) diabetes; (9) kidney diseases; (10) eye diseases and disorders, including glaucoma; (11) HIV/AIDS and sexually transmitted infections; (12) uterine fibroids; (13) autoimmune disease; (14) mental health conditions; (15) dental health conditions and oral diseases, including oral cancer; (16) environmental and related health illnesses and conditions; (17) sickle cell disease and sickle cell trait; (18) violence and injury prevention and control; (19) genetic and related conditions; (20) heart disease and stroke; (21) tuberculosis; (22) chronic obstructive pulmonary disease; (23) musculoskeletal diseases, arthritis, and obesity; and (24) other diseases determined appropriate by the Secretary. (d) Dissemination Not later than 2 years after the date of enactment of this Act, the Secretary shall publish and disseminate to health care provider organizations the guidelines developed under subsection (a). (e) Authorization of appropriations There are authorized to be appropriated to carry out this section such sums as may be necessary for each of fiscal years 2019 through 2023. 732. CDC Wisewoman Screening Program Section 1509 of the Public Health Service Act ( 42 U.S.C. 300n–4a ) is amended— (1) in subsection (a)— (A) by striking the heading and inserting In General .—